ArticleJournal of pain research2025
Identification and Experimental Verification of Potential Immune Cell-Associated Gene Biomarkers in Human Intervertebral Disc Degeneration.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Intervertebral disc degeneration (IDD) is one of the most common diseases in the elderly population. Recently, immune disorders have been considered to play an important role in IDD. This study aimed to conduct a bioinformatic analysis to identify biomarkers associated with IDD immune cells. Methods: We obtained the gene expression profiles of IDD by downloading the Gene Expression Omnibus Series (GSE)150408 and GSE124272 from the Gene Expression Omnibus (GEO) database. IDD and immune cell-related hub genes were identified via multiple bioinformatics analyses, and their diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. In addition, a long non-coding RNA (lncRNA)-signature gene co-expression network was constructed. Finally, the diagnostic accuracy of the biomarkers was verified using Real-time quantitative PCR (RT-qPCR). Results: ASAP1-IT1, IKZF2, KLHL14, lnc-C10orf131-1, and LOC101927805 were identified as signature genes of IDD. Further, ROC analysis revealed that the five signature gene models had a strong ability to discriminate between the IDD and healthy control samples. We also found that the five signature genes were significantly associated with immune-inflammatory feedback, cell cycle, and skeletal system. Furthermore, an lncRNA signature gene network was constructed to reveal the regulatory mechanisms of the biomarkers. Finally, RT-qPCR results verified that IKZF2 and KLHL14 were significantly downregulated in patients with IDD, and ASAP1-IT1 was significantly upregulated. Conclusion: This study identified ASAP1-IT1, IKZF2, and KLHL14 as the key signature genes of IDD. These key hub genes may serve as potential therapeutic targets for IDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.